A total 5,946 cows from 24 dairy farms were carried out for the improvement of reproductive performance. Dairy cows in post-parturition 30 day were performed periodic reproductive examination to check for recovery of post-parturition ovary and uterus and for the early diagnosis of reproductive disease. The results obtained from this studies were as follow. The result of 1,126 cows with ovario-uterine disease were 579 slient heat and error of estrus detection (51.4%), 296 ovarian disease (26.3%), 248 uterine disease (22%), mummification and freematin were each 1 head (0.1%), respectively. Hormonal therapeutic effects were follicular cyst 81.5%, luteal cyst 90.7%, endometritis 86.9%, mucometra 90.1%, pyometra 60.9%, respectively. In cows, even if the 1st treatment fails, 2nd, 3rd treatment were performed. Therapeutic effect of 2nd, 3rd were reduced, but the number of cured cows were gradually increased. The cured cows after hormonal treatment were performed service repeatedly and the cumulative conception rate were increased. The cows treated with hormones at first service, the conception rate were follicular cyst 26%, luteal cyst 64.1%, endometritis 38.7%, mucometra 40%, pyometra 20.5%, respectively. The cumulative conception rates were increased by repeated service follicular cyst 57.3%, luteal cyst 84.6%, endometritis 67%, mucometra 75%, pyometra 64.1%, respectively.

Central precocious puberty (CPP) is less common in boys than girls; very little data is reported on effect of gonadotropin-releasing hormone analog (GnRHa) treatment in boys with CPP. The aim of the study was to evaluate growth changes in boys with CPP and early puberty (EP) treated with GnRHa therapy for 1 year. In 60 (39 CPP and 21 EP) boys with confirmed diagnosis of CPP and EP, auxological [height, height standard deviation score (Ht SDS), bone age (BA), Predicted adult height (PAH)] and endocrinological parameters were obtained at baseline, at 6 months, and at 1 year after GnRHa treatment in boys with CPP and EP. During the treatment a decline in Ht SDS and growth velocity, luteinizing hormone (LH), follicle stimulating hormone (FSH) and testosterone levels were observed (p＜0.01); and a deceleration in the maturation of bones after 1 year GnRHa treatment was observed (p＜0.01). PAH SDS was increased during treatment with GnRHa (p＜0.01). There was significant difference in PAH SDS between organic CPP and non-organic CPP (p＜0.05). The present data indicate that GnRHa therapy significantly improves growth prognosis in boys with CPP and EP.